



ADVANCES IN HEPATOLOGY – FROM MECHANISTIC INSIGHTS TO NOVEL THERAPEUTIC CONCEPTS

October 24-25, 2025

Symposium 242
BERLIN, GERMANY



APPLICATION
FOR **CME**
CREDITS
SUBMITTED

Preface	2
Scientific Program	4
International Herbert Falk Award	10
List of Speakers, Moderators and Scientific Organizers	14
Posters	20
Information	21



An application has been made to the UEMS EACCME® for CME accreditation of this event. The number of credits awarded will be printed in the final program.

PREFACE

Dear colleagues and friends,

It is with great pleasure that we welcome you to our international symposium, *Advances in Hepatology*, a unique gathering that brings together leading minds from across the globe to explore the latest advancements in the understanding and treatment of liver diseases. This meeting represents a confluence of diverse expertise, from basic science to clinical practice, and offers a platform to foster collaboration, inspire innovation, and pave the way toward transformative breakthroughs in hepatology.

Liver diseases remain a significant global health challenge, with far-reaching impacts on millions of lives. The focus of this year's conference is on new mechanisms and therapies, and our program reflects this emphasis with cutting-edge sessions on topics such as liver fibrosis, cholestatic liver diseases, metabolic liver disease / MASLD, viral hepatitis, and liver cancer. These sessions will delve into the molecular and cellular mechanisms underlying disease progression, as well as emerging therapeutic strategies, including precision medicine, disease monitoring strategies, novel drug targets, and advanced technologies like organoids, single-cell omics and artificial intelligence.

We are proud to host an outstanding lineup of internationally renowned speakers who will share their groundbreaking research and clinical insights. In addition to the plenary sessions, the conference will feature interactive panel discussions, poster presentations, and networking opportunities, ensuring a dynamic and engaging experience for all participants.

This event is not only an opportunity to learn from the best but also a chance to contribute to the future of hepatology. By fostering an open exchange of ideas and building connections across disciplines, we aim to create an environment that inspires innovation and advances the care of patients with liver diseases. We are grateful to the Falk Foundation for providing us this unique platform of international exchange at the symposium.

We look forward to welcoming you to what promises to be an intellectually stimulating and highly rewarding conference in Berlin. Together, let us explore the frontiers of hepatology and work toward a healthier future.

Warm regards,

Stefan Fichtner-Feigl Tom Hemming Karlsen Sophie Lotersztajn Frank Tacke

ADVANCES IN HEPATOLOGY – FROM MECHANISTIC INSIGHTS TO NOVEL THERAPEUTIC CONCEPTS

October 24-25, 2025

Scientific Organization:

Stefan Fichtner-Feigl, Freiburg (Germany)
Tom Hemming Karlsen, Oslo (Norway)
Sophie Lotersztajn, Paris (France)
Frank Tacke, Berlin (Germany)

Congress Venue:

JW Marriott Hotel Berlin
Stauffenbergstr. 26
10785 Berlin
Germany

For admission to scientific events your name badge should be clearly visible.

Accompanying persons are not permitted during the conference at any time.

Call for Posters:

An ePoster session will be held. For details see page 16.

Start of Registration:

Thursday, October 23, 2025
16:00-20:00 h
at the congress office

Publication Date of the Final Program:

October 2025

The final program will be available on the website www.falkfoundation.org one week before the start of the symposium.

Friday, October 24, 2025

09:00 Welcome
*Stefan Fichtner-Feigl, Freiburg; Tom H. Karlsen, Oslo;
Sophie Lotersztajn, Paris; Frank Tacke, Berlin*

SESSION I

Current developments in hepatology

Chairs: *Robert Thimme, Freiburg; Jessica Zucman-Rossi, Paris*

09:10 Keynote lecture: Trends and challenges in hepatology in 2025
Arun J. Sanyal, Richmond

09:30 Liver disease burden in 2025
Zobair Younossi, Washington DC

09:50 Liver biology at single-cell resolution
Sonya MacParland, Toronto

10:10 Liver disease modelling
Ludovic Vallier, Berlin

10:30 **Coffee break with ePoster session**

SESSION II

Mechanisms of injury, inflammation, fibrosis

Chairs: *Sophie Lotersztajn, Paris; Massimo Pinzani, Palermo*

11:00 Fibrosis progression and regression: An integrated view
Robert Schwabe, New York

11:20 Liver immunology in the era of multi-omics data
Charlotte Scott, Ghent

11:40 Metabolic reprogramming in liver injury
Catherine Postic, Paris

Poster pitches

Chairs: *Sophie Lotersztajn, Paris; Massimo Pinzani, Palermo*

12:00 Basic and translational science
(5 poster pitches)

12:30 **Lunch break with ePoster session**

SESSION III

Cholestatic liver diseases

Chairs: *Michael P. Manns, Hannover; Palak Trivedi, Birmingham*

14:00 Management of primary biliary cholangitis: Current algorithms
Christophe Corpechot, Paris

14:20 Management of concurrent inflammatory bowel disease and primary sclerosing cholangitis
Britta Siegmund, Berlin

14:40 The translational journey of drug development in cholangiopathies
Part 1: From bile acid pathobiology to therapeutic actions of Norucholic acid
Peter Fickert, Graz
Part 2: Clinical development and trial results with Norucholic acid
Michael Trauner, Vienna

Panel discussion

Chair: *Michael P. Manns, Hannover*

15:10 Current management of primary sclerosing cholangitis
Verena Keitel-Anselmino, Magdeburg; Tom H. Karlsen, Oslo; Michael Trauner, Vienna; Palak Trivedi, Birmingham

15:30 **Coffee break with ePoster session**

INTERNATIONAL HERBERT FALK AWARD

- 16:00** Presentation of the International Herbert Falk Award
Jürgen Schölmerich, Hofheim
- 16:10** International Herbert Falk Award Lecture: What hepatologists can learn from the discovery of pancreatic stellate cells
Minoti Apte, Sydney

SESSION IV

New avenues for liver diseases

Chairs: *Paolo Angeli, Padova; Thomas Berg, Leipzig*

- 16:30** Viral hepatitis: Challenging current dogmas on hepatitis B and on delta
Heiner Wedemeyer, Hannover
- 16:50** Genetic cholestasis: Diagnosis and management
Verena Keitel-Anselmino, Magdeburg
- 17:10** Alcohol-associated liver diseases: How can we leverage the developments from the MASLD field?
Alexandre Louvet, Lille
- 17:30** New therapeutic modalities: New opportunities for hepatology? (CAR-T cells, siRNA, CRISPR-Cas9...)
Rohit Loomba, San Diego

Saturday, October 25, 2025

SESSION V

From monitoring liver disease progression to pathways of care

Chairs: *Annalisa Berzigotti, Bern; Rohit Loomba, San Diego*

09:00 Do we need a non-invasive liver health check in the general population?
Maja Thiele, Odense

09:20 Blood-based and imaging biomarkers for monitoring liver disease progression and treatment responses: Are we there yet?
Vincent Wong, Hongkong

09:40 The microbiome as a diagnostic tool and a therapeutic target in liver diseases
Bernd Schnabl, San Diego

10:00 Is digital pathology ready for routine clinical practice?
Jakob N. Kather, Dresden

10:20 **Coffee break with ePoster session**

SESSION VI

Challenges in advanced liver diseases

Chairs: *Patrizia Burra, Padova; Cornelius Engelmann, Berlin*

10:50 Portal hypertension: What to expect from Baveno VIII?
Annalisa Berzigotti, Bern

11:10 Acute-on-chronic liver failure: Evidence-based management
Paolo Angeli, Padova

11:30 Moving boundaries in liver transplantation: Obesity, cholangiocarcinoma, alcohol
Julie Heimbach, Rochester

Poster pitches

Chairs: *Thomas Berg, Leipzig; Stefan Fichtner-Feigl, Freiburg*

11:50 Clinical science
(5 poster pitches)

12:20 Lunch break with ePoster session

SESSION VII

Hepatocellular and cholangiocellular carcinoma

Chairs: *Johann Pratschke, Berlin; Lorenza Rimassa, Milan*

13:20 Therapeutic relevance of the molecular landscape in liver cancer
Jessica Zucman-Rossi, Paris

13:40 Functional relevance of the immunological environment in liver cancer
Mathias Heikenwälder, Heidelberg

14:00 The therapeutic (r)evolution in managing liver cancer
Bruno Sangro, Pamplona

14:20 Moving boundaries in surgery for liver cancer
Iswanto Sucandy, Tampa

14:40 **Awards for best presentations (posters + poster pitches)**
Stefan Fichtner-Feigl, Freiburg; Tom H. Karlsen, Oslo;
Sophie Lotersztajn, Paris; Frank Tacke, Berlin

15:00 Coffee break with ePoster session

SESSION VIII

MASLD: The biggest challenge in hepatology?

Chairs: *Patrizia Burra, Padova; Münevver Demir, Berlin*

- 15:30** Management of obesity and type 2 diabetes: Lessons for the hepatologist
Cyrielle Caussy, Pierre-Bénite
- 15:50** The next generation of risk stratification algorithms in MASLD
Elisabetta Buggianesi, Torino
- 16:10** The evolving landscape of pharmaceutical therapies in MASLD management
Vlad Ratziu, Paris

Panel discussion

Chair: *Patrizia Burra, Padova*

- 16:30** Current medical therapies in MASLD management
Cyrielle Caussy, Pierre-Bénite; Vlad Ratziu, Paris; Frank Tacke, Berlin
- 16:50** Closing Remarks
Stefan Fichtner-Feigl, Freiburg; Tom H. Karlsen, Oslo; Sophie Lotersztajn, Paris; Frank Tacke, Berlin

HERBERT FALK (1924 - 2008)



Herbert Falk was born in 1924 in Müllheim, a small town in South-West Germany between Freiburg and Basle, where his father ran a pharmacy. It was here that Herbert Falk spent his early years, attending primary school and high school up to the 5th grade. His parents then moved to Freiburg, where his father had his own pharmacy. On gaining his university entrance diploma from the Rotteck high school in March 1942, he was immediately called up for military service. During the Second World War he served on the front line in North Africa as a soldier with the Africa Corps and narrowly escaped death several times. At the end of the North Africa campaign, he was captured and transferred to the USA as a prisoner of war, spending his final year of captivity in England.

On his release and return to Germany, Herbert Falk studied pharmacy then medicine at the University of Freiburg. He graduated and received his doctor's degree in both subjects. Thereafter, he took over the pharmacy in Freiburg from his father.

After several years of success as a pharmacist, Herbert Falk made the decision which would prove so crucial for his future life's journey and founded his own company, producing and marketing pharmaceuticals for application in gastroenterological and hepatological diseases. Within a few years, his abundant energy, determined pursuit of goals, untiring diligence, keen eye for promising research developments, and not least his legendary talent for organization, had turned his pharmaceutical company into a global enterprise world famous in specialist circles. Falk products are meanwhile highly acclaimed not only in Germany and other European countries but also in South America, countries of the Near and Far East, Russia, China and Australia.

Herbert Falk's contributions to research were founded not on his own scientific work but on his organization of symposia, workshops and other scientific congresses which he sponsored and promoted to an extraordinary level and with great personal dedication. International Falk Symposia, workshops and congresses have won global recognition. There are several reasons for this:

- In addition to numerous advanced medical education programs for doctors organized by the Falk Foundation, which are primarily or exclusively concerned with issues of medical practice, the foundation also organizes symposia, workshops and congresses. These feature in-depth

lectures and critical discussions on questions and findings of biomedical basic sciences as well as their application in diagnostic measures, diagnostic decision-making, disease prevention and therapy.

- Leading researchers from a particular field and clinical-medical experts are invited to Falk Symposia as speakers or discussion leaders, enabling comparison within a field at an international level. The scientific organizers have a completely free hand in their choice of topics and selection of speakers. This gives symposia participants an opportunity to acquire first-hand knowledge of the latest findings in their field.
- Falk Symposia are the ideal opportunity for representatives of biomedical basic research, clinical research and physicians working in clinic and practice to meet and exchange opinions. Participants benefit enormously from this fertile interchange of personal experiences, critical viewpoints and valuable suggestions for further work.
- Not least, Falk Symposia are of great significance for the new medical and scientific generation in Germany, since they provide an opportunity for young doctors and scientists to encounter internationally renowned scientists from the field of gastroenterology who can answer their queries and assist their further progress by offering constructive criticism, suggestions and encouragement. A frequent outcome of these encounters is the opportunity for young German scientists to spend a lengthy period abroad as guests in the laboratories or clinical institutions of foreign researchers.

It was Herbert Falk's personality which gave the symposia their unique stamp. His generous support of organizers and speakers, intuitive flair for innovative developments, extraordinary talent for organization and overwhelming hospitality have turned Falk Symposia, workshops and congresses into scientific events of international esteem and renown.

Herbert Falk received many honors and distinctions for his outstanding achievements as a sponsor of biomedical and clinical research and patron of the upcoming medical-scientific generation. These included honorary membership of numerous national and international gastroenterological and hepatological societies. He was made an honorary doctor of the medical faculties of the Universities of Cluj-Napoca (Romania), Basle and Freiburg. The German Medical Association commended him for his services by awarding him the Ernst von Bergmann Plakette. In 2004, the American Gastroenterological Association (AGA) honored him with its highest distinction: The Lifetime Distinguished Service Award.

The portrait of Herbert Falk would not be complete without mentioning some key aspects and traits of his personality. Despite his multifaceted success in the development of his pharmaceutical company and the many honors he received, Herbert Falk remained a man of great humility in his personal dealings with the people around him. His friends and co-workers could rely on him implicitly to fulfill any decision or promise which had been made. He always had an open ear for constructive criticism. His joie de vivre and positive attitude to life remain unforgettable. Especially memorable is the pleasure he took in the culinary delights of kitchen and cellar. On such festive occasions he would strike up the “Badener Lied”, the hymn to his beloved native area of Baden. The unique beauty of this countryside - so dear to him from countless hikes through the Black Forest - never ceased to fascinate him. This was where he felt at home. This was where he found the strength and inspiration he needed for his work.

Herbert Falk continued to contribute to the development of his company into a ripe old age. He kept up to date with the latest international research projects in the fields of gastroenterology and hepatology, showing a keen interest, critical discernment and sure instinct for quality. He did not give up his leading role in the company until the end of 2003, when he was nearly 80 years of age.

In 2008, a serious illness borne with admirable equanimity brought his life to an end. His memory, life’s work and services will live on through the Herbert Falk Prize.

Wolfgang Gerok, Freiburg (†)

INTERNATIONAL HERBERT FALK AWARD 2025

The International Herbert Falk Award will be presented for the 6th time by the Falk Foundation e.V. on the occasion of Symposium 242 in Berlin in October 2025. The prize amounts to EUR 40.000,- and is awarded for outstanding contributions to gastroenterology and hepatology, including advances in diagnosis, therapy and prevention.

MEMBERS OF THE PRIZE COMMITTEE:

M.M. Lerch, München (Germany)
A. Schoepfer, Lausanne (Switzerland)
J. Schölmerich, Hofheim (Germany)
R.C. Spiller, Nottingham (Great Britain)
H. Wedemeyer, Hannover (Germany)

COORDINATOR OF THE INTERNATIONAL HERBERT FALK AWARD COMMITTEE:

Prof. Dr. Jürgen Schölmerich
Germanenstr. 8b
65719 Hofheim
Germany

LIST OF SPEAKERS, MODERATORS AND SCIENTIFIC ORGANIZERS

Prof. Paolo Angeli

Dipartimento di Medicina - DIMED
University of Padova
Via Giustiniani, 2
35128 Padova
Italy
pangeli@unipd.it

Prof. Dr. Minoti Apte

Pancreatic Research Group
School of Clinical Medicine, UNSW
Medicine & Health
UNSW Sydney
Level 4, Ingham Institute for Applied
Medical Research
1 Campbell Street, Liverpool, NSW 2170
Australia
m.apte@unsw.edu.au

Prof. Dr. Thomas Berg

Klinik und Poliklinik für Onkologie,
Gastroenterologie, Hepatologie und
Pneumologie
Universitätsklinikum Leipzig
Liebigstr. 20
04103 Leipzig
Germany
thomas.berg@medizin.uni-leipzig.de

Prof. Dr. Annalisa Berzigotti

Department of Visceral Surgery and
Medicine
Inselspital Bern University Hospital
Freiburgstr. 10
3008 Bern
Switzerland
annalisa.berzigotti@insel.ch

Dr. Elisabetta Bugianesi

Department of Medical Science
University of Torino
Via Giuseppe Verdi, 8
10124 Torino
Italy
elisabetta.bugianesi@unito.it

Prof. Dr. Patrizia Burra

Department of Surgery, Oncology and
Gastroenterology
University of Padova
Via Giustiniani, 2
35128 Padova
Italy
burra@unipd.it

Cyrielle Caussy, MD, PhD

Endocrinologie Diabétologie Nutrition
Centre Hospitalier Lyon Sud
165 Chemin du Grand Revoyet
69495 Pierre-Bénite
France
cyrielle.caussy@chu-lyon.fr

Dr. Christophe Corpechot

Reference center for inflammatory
biliary diseases and autoimmune
hepatitis
Hopital Saint-Antoine
Assistance Publique - Hôpitaux de
Paris & Sorbonne University
184, rue du Faubourg Saint-Antoine
75571 Paris Cedex 12
France
christophe.corpechot@aphp.fr

Prof. Dr. Münevver Demir

Medizinische Klinik mit Schwerpunkt
Hepatologie und Gastroenterologie
Charité - Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin
Germany
muenevver.demir@charite.de

Dr. Cornelius Engelmann

Hepatologie und Gastroenterologie
Charité - Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin
Germany
cornelius.engelmann@charite.de

Prof. Dr. Stefan Fichtner-Feigl

Klinik für Allgemein- und
Viszeralchirurgie
Universitätsklinikum Freiburg
Hugstetter Str. 55
79106 Freiburg
Germany
stefan.fichtner@uniklinik-freiburg.de

Prof. Dr. Peter Fickert

Division of Gastroenterology and
Hepatology
Department of Internal Medicine
Medical University of Graz
Auenbruggerplatz 15
8036 Graz
Austria
peter.fickert@medunigraz.at

Prof. Dr. Mathias Heikenwälder

Deutsches Krebsforschungszentrum
DKFZ
Chronische Entzündung und Krebs
Im Neuenheimer Feld 280
69120 Heidelberg
Germany
m.heikenwaelder@dkfz-heidelberg.de

Julie K. Heimbach, MD

Transplant Center
Mayo Clinic-Rochester
200 1st street SW
55905 Rochester, MN
USA
heimbach.julie@mayo.edu

Prof. Dr. Tom Hemming Karlsen

Oslo University
Postboks 4950
Nydalén
OUS, Rikshospitalet
0424 Oslo
Norway
t.h.karlsen@medisin.uio.no

Dr. Jakob Nikolas Kather

Medizinische Klinik und Poliklinik I
Technische Universität Dresden
Fetscherstr. 74
01307 Dresden
Germany
jakob.kather@tu-dresden.de

Prof. Dr. Verena Keitel-Anselmino

Universitätsklinik für Gastroenterologie, Hepatologie und Infektiologie
Universitätsklinikum Magdeburg A.ö.R.
Leipziger Str. 44
39120 Magdeburg
Germany
verena.keitel-anselmino@med.ovgu.de

Prof. Rohit Loomba, MD, MHSc

Division of Gastroenterology & Hepatology
University of California at San Diego
9452 Medical Center Drive
La Jolla, CA, 92037
USA
roloomba@ucsd.edu

Dr. Sophie Lotersztajn

Medical Research
Inserm - Center for Research on Inflammation
16 rue Henri Huchard
75018 Paris
France
sophie.lotersztajn@inserm.fr

Prof. Dr. Alexandre Louvet

Department of Hepatology and Gastroenterology
University Hospital of Lille
Rue Michel Polonovski
59000 Lille
France
alexandre.louvet@chru-lille.fr

Dr. Sonya MacParland

Department of Laboratory Medicine & Pathobiology
University of Toronto
Office 2-308 101 College Street
Toronto, M5G 1L7
Canada
s.macparland@utoronto.ca

Prof. Dr. Michael Peter Manns

Vorstand Ressort Forschung und Lehre
Medizinische Hochschule Hannover (MHH)
Carl-Neuberg-Str. 1
30625 Hannover
Germany
manns.michael@mh-hannover.de

Prof. Massimo Pinzani

ISMETT
Via E. Tricomi 5
90127 Palermo
Italy
m.pinzani@ucl.ac.uk

Catherine Postic

Institut Cochin
22, rue Mechain
75014 Paris
France
catherine.postic@inserm.fr

Univ.-Prof. Dr. Johann Pratschke

Chirurgische Klinik
Campus Charité Mitte | Campus
Virchow-
Klinikum
Charité - Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin
Germany
johann.pratschke@charite.de

Prof. Vlad Ratziu

Hospital Pitié Salpêtrière
Sorbonne Université
47 -83 Bd de l'Hôpital
75013 Paris
France
vlad.ratziu@inserm.fr

Lorenza Rimassa, MD

Department of Biomedical Sciences
Humanitas University
Medical Oncology and Hematology Unit
Humanitas Cancer Center
IRCCS Humanitas Research Hospital
Via Rita Levi Montalcini, 4
20072 Pieve Emanuele (Milano)
Italy
lorenza.rimassa@hunimed.eu

Dr. Bruno Sangro

Liver Unit
Clinica Universidad de Navarra
Avda Pio XII 36
31008 Pamplona
Spain
bsangro@unav.es

Arun J. Sanyal, MD

Gastroenterology
VCU Medical Center
1201 E. Marshall St.
23298 Richmond, VA
USA
arun.sanyal@vcuhealth.org

Prof. Dr. Bernd Schnabl

UCSD School of Medicine, Division of
Gastroenterology, Department of
Medicine, University of CA
9500 Gilman Drive
CA 92093 La Jolla
USA
beschnabl@health.ucsd.edu

Prof. Dr. Jürgen Schölmerich

Germanenstr. 8b
65719 Hofheim
Germany
jschoelmerich@gmx.de

Prof. Robert F. Schwabe, MD

Digestive and Liver Disease Research
Center (CU-DLDRC)
Columbia University
1130 St. Nicholas Avenue
NY 10032 New York
USA
rfs2102@cumc.columbia.edu

Prof. Charlotte Scott, PhD

Center for Inflammation Research
Professor WE14 Faculty of Sciences
VIB-Ugent
Technologiepark-Zwijnaarde 71
9052 Ghent
Belgium
charlotte.scott@irc.vib-ugent.be

Prof. Dr. Bitta Siegmund

Medizinische Klinik I - Gastroenterologie/
Infektiologie/Rheumatologie
Charité - Universitätsmedizin Berlin
Hindenburgdamm 30
12203 Berlin
Germany
britta.siegmund@charite.de

Iswanto Sucandy, MD, FACS

AdventHealth Tampa -
Digestive Health Institute
Hepatopancreatobiliary (HPB) and
Robotic Surgery
3000 Medical Park Drive
Suite # 500
Tampa, FL 33613
USA
iswanto.sucandy.md@adventhealth.com

Prof. Dr. Frank Tacke

Medizinische Klinik mit Schwerpunkt
Hepatology und Gastroenterologie
Charité - Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin
Germany
frank.tacke@charite.de

Prof. Maja Thiele

FLASH - Fibrosis, Fatty Liver and
Steatohepatitis Research Centre
Odense
Department of Gastroenterology and
Hepatology
Odense University Hospital and
University of Southern Denmark
Campusvej 55
5230 Odense M
Denmark
mthiele@health.sdu.dk

Prof. Dr. Robert Thimme

Klinik für Innere Medizin II
Universitätsklinikum Freiburg
Hugstetter Str. 55
79106 Freiburg
Germany
robert.thimme@uniklinik-freiburg.de

Prof. Dr. Michael Trauner

Klinische Abteilung für Gastroenterologie
& Hepatologie
Medizinische Universität Wien
Währinger Gürtel 18-20
1090 Wien
Austria
michael.trauner@meduniwien.ac.at

Dr. Palak Trivedi

Centre for Liver and Gastrointestinal
Research
Institute of Immunology and
Immunotherapy
University of Birmingham
ITM Building, Mindelsohn Way
Edgbaston Birmingham, B15 2TT
UK
p.j.trivedi@bham.ac.uk

Prof. Dr. Ludovic Vallier

Berlin Institute of Health (BIH)
Charité - Universitätsmedizin Berlin
Campus Virchow-Klinikum
Augustenburger Platz 1
13353 Berlin
Germany
ludovic.vallier@bih-charite.de

Prof. Dr. Heiner Wedemeyer

Klinik für Gastroenterologie, Hepatologie,
Infektiologie und Endokrinologie
Medizinische Hochschule Hannover
Carl-Neuberg-Str. 1
30625 Hannover
Germany
wedemeyer.heiner@mh-hannover.de

Prof. Vincent Wai-Sun Wong

Department of Medicine and
Therapeutics
Faculty of Medicine
The Chinese University of Hong Kong
9/F, Prince of Wales Hospital
ShaTin
Hongkong
wongv@mect.cuhk.edu.hk

Zobair M. Younossi, MD, MPH

Global NASH Council
Beatty Liver and Obesity Research,
Inova Health System
Department of Medicine, Inova Fairfax
Medical Campus
2411 I Street
Washington DC 20023
USA
zobair.younossi@cldq.org

Prof. Jessica Zucman-Rossi

Centre de Recherche des Cordeliers
Sorbonne Université – Inserm
Université Paris Cité
15 rue de l'école de Médecine
Esc A, 1st Floor
75006 Paris
France
jessica.zucman-rossi@inserm.fr

POSTER SESSION

ePosters will be exhibited on our ePoster screens on October 24-25, 2025. The authors will be in attendance during coffee and lunch breaks on both days.

CALL FOR POSTERS

Please submit your poster abstract before July 23, 2025.

Abstracts must be submitted via our Internet Abstract Submission System (<https://poster.falkfoundation.com>) where further information regarding the submission format and the submission process is available.

The abstracts will be selected by the scientific organizers, with preference being given to those thematically related to one of the sessions of the congress. The accepted abstracts will be published in the final program of the meeting.

Poster authors will receive notification about acceptance and further instructions in August, 2025.

For the first author of an accepted poster, accommodation expenses (October, 23-26, 2025) and fees for the scientific program will be covered during Symposium 242. Travel expenses will not be covered.

POSTER AWARDS

Three prizes will be awarded for the best poster presentations. Winners will be asked to give a short presentation (2-5 minutes) of their poster during the award ceremony.

Award winners will be presented with a certificate and prize money.

Travel expenses will also be covered for the first authors of the three winning posters.

REGISTRATION



You can register for the event via our homepage:

www.falkfoundation.org

Registration is only possible online.

You will receive an automatic confirmation of registration by e-mail. Please transfer the congress fee to the bank account listed in the e-mail within two weeks.

CONGRESS FEES

Scientific Program of Symposium 242	EUR 300
Students (copy of student ID required)	EUR 150

The congress fees include:

- Pre-Opening and Welcome on Thursday, October 23, 2025
- Refreshments during coffee breaks
- Lunch on Friday and Saturday, October 24-25, 2025
- A copy of the final program

CONGRESS OFFICE AND REGISTRATION

Opening Hours:

Thursday, October 23, 2025	16:00 – 20:00 h
Friday, October 24, 2025	08:00 – 17:30 h
Saturday, October 25, 2025	08:00 – 17:00 h

The Falk Foundation will take pictures during the meeting. Additionally, parts of the meeting might be recorded. By participating all attendees consent and agree with the recording and the photo shoots.

GENERAL INFORMATION

The event “Advances in Hepatology - from Mechanistic Insights to Novel Therapeutic Concepts, Symposium 242 Berlin, Germany” is organized by the Falk Foundation e.V.

The Falk Foundation covers the travel expenses for speakers as well as their hotel and registration costs. The Falk Foundation e.V. also bears the costs for catering, room rental and technical equipment. The organizer is associated with Dr. Falk Pharma GmbH.

ARRIVAL

JW Marriott Hotel Berlin

Stauffenbergstr. 26
10785 Berlin
Germany

By plane

The Berlin Brandenburg Airport (BER) is about 26.5 km away from the hotel and well connected with trains departing from Terminal 1-2 every hour. You can also take a taxi which takes about 30 minutes time.

By train

Berlin Central Station (U-Bahn, S-Bahn, regional trains, ICE train)

Station Potsdamer Platz (U-Bahn, S-Bahn, regional trains)

From Station Potsdamer Platz: Head west on Potsdamer Platz/B1.

Turning right toward Sigismundstrasse. Slight right onto Sigismundstrasse. Turn left onto Stauffenbergstrasse. Destination will be on the left.

By car

On-Site Parking

Hourly: €3.00

Daily: €25.00

the 1990s, the number of people in the world who are under 15 years of age is expected to increase from 1.1 billion to 1.5 billion (United Nations 1998).

There are a number of reasons why the number of children in the world is increasing. One of the main reasons is the decline in the death rate of children under 5 years of age. In 1990, 10.6 million children under 5 years of age died, but by 2000, this number is expected to fall to 6.5 million (United Nations 1998).

Another reason is the increase in the number of children in the world who are under 15 years of age. In 1990, there were 1.1 billion children under 15 years of age, but by 2000, this number is expected to increase to 1.5 billion (United Nations 1998).

The increase in the number of children in the world is a result of a combination of factors. One of the main factors is the decline in the death rate of children under 5 years of age. Another factor is the increase in the number of children in the world who are under 15 years of age.

The increase in the number of children in the world is a result of a combination of factors. One of the main factors is the decline in the death rate of children under 5 years of age. Another factor is the increase in the number of children in the world who are under 15 years of age.

The increase in the number of children in the world is a result of a combination of factors. One of the main factors is the decline in the death rate of children under 5 years of age. Another factor is the increase in the number of children in the world who are under 15 years of age.

The increase in the number of children in the world is a result of a combination of factors. One of the main factors is the decline in the death rate of children under 5 years of age. Another factor is the increase in the number of children in the world who are under 15 years of age.

The increase in the number of children in the world is a result of a combination of factors. One of the main factors is the decline in the death rate of children under 5 years of age. Another factor is the increase in the number of children in the world who are under 15 years of age.

The increase in the number of children in the world is a result of a combination of factors. One of the main factors is the decline in the death rate of children under 5 years of age. Another factor is the increase in the number of children in the world who are under 15 years of age.


The increase in the number of children in the world is a result of a combination of factors. One of the main factors is the decline in the death rate of children under 5 years of age. Another factor is the increase in the number of children in the world who are under 15 years of age.

The increase in the number of children in the world is a result of a combination of factors. One of the main factors is the decline in the death rate of children under 5 years of age. Another factor is the increase in the number of children in the world who are under 15 years of age.

The increase in the number of children in the world is a result of a combination of factors. One of the main factors is the decline in the death rate of children under 5 years of age. Another factor is the increase in the number of children in the world who are under 15 years of age.



**Registration via www.falkfoundation.org
or simply scan and register.**



Together we know more. Together we do more.

Falk Foundation e.V. | Leinenweberstr. 5 | 79108 Freiburg | Germany
T: +49 761 1514-400 | F: +49 761 1514-460 | E-Mail: meeting@falkfoundation.org
www.falkfoundation.org